Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.53 |
| ▸ | ACACA | Q13085 | 4/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547268 | 0.88 | ACACB (0.62) | ACACBACACA | |
| SCHEMBL1547571 | 0.87 | ACACB (0.45) | ACACBACACAFFAR1PPARGPPARD | |
| SCHEMBL19984479 | 0.84 | ACACB (0.55) | ACACBACACAFFAR1PPARGPPARD | |
| SCHEMBL2169083 | 0.83 | ACACB (0.66) | ACACBACACA | |
| SCHEMBL1547440 | 0.82 | ACACB (0.48) | ACACBACACAFFAR1PPARGPPARD | |
| SCHEMBL5943027 | 0.80 | ACACB (0.52) | ACACBACACALTA4H | |
| SCHEMBL13047644 | 0.78 | ACACB (0.56) | ACACBACACAFFAR1PPARGPPARD | |
| SCHEMBL1547269 | 0.78 | ACACB (0.50) | ACACBACACAFFAR1 | |
| SCHEMBL1547599 | 0.75 | ACACB (0.53) | ACACBACACAFFAR1MAOBGAA | |
| SCHEMBL18026569 | 0.73 | ACACB (0.77) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470841-B2 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | SANOFI (FR) | 2013-06-25 | — | — | US | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | CS, CYP11B1, GPR119 | ACACB 1290/4885ACACA 1283/4885FFAR1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.